| Primary |
| Pneumonia |
23.4% |
| Infection |
15.7% |
| Sepsis |
10.0% |
| Hypertension |
7.3% |
| Pyrexia |
5.1% |
| Urinary Tract Infection |
4.3% |
| Pseudomonas Infection |
3.4% |
| Bacteraemia |
3.2% |
| Septic Shock |
3.0% |
| Pain |
3.0% |
| Pneumonia Aspiration |
2.8% |
| Prophylaxis |
2.8% |
| Bacterial Infection |
2.3% |
| Febrile Bone Marrow Aplasia |
2.2% |
| Diabetes Mellitus |
2.0% |
| Febrile Neutropenia |
2.0% |
| Endocarditis |
2.0% |
| Pancreatitis Acute |
1.9% |
| Peritonitis |
1.9% |
| Interstitial Lung Disease |
1.7% |
|
| Convulsion |
17.4% |
| Death |
7.8% |
| Sepsis |
7.8% |
| Drug Ineffective |
7.1% |
| Thrombocytopenia |
6.1% |
| Treatment Failure |
6.1% |
| Epilepsy |
5.9% |
| Septic Shock |
5.9% |
| Toxic Epidermal Necrolysis |
4.2% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.0% |
| Liver Disorder |
3.8% |
| Pneumonia |
3.8% |
| Stevens-johnson Syndrome |
3.4% |
| Hepatic Function Abnormal |
3.1% |
| Tremor |
2.5% |
| Pyrexia |
2.3% |
| Rash |
2.3% |
| Rhabdomyolysis |
2.3% |
| Shock |
2.3% |
| Pancytopenia |
2.1% |
|
| Secondary |
| Pneumonia |
16.7% |
| Infection |
11.1% |
| Drug Use For Unknown Indication |
11.0% |
| Product Used For Unknown Indication |
6.2% |
| Sepsis |
6.1% |
| Hypertension |
5.5% |
| Pyrexia |
5.3% |
| Urinary Tract Infection |
4.7% |
| Bacterial Infection |
4.1% |
| Pancytopenia |
3.8% |
| Febrile Bone Marrow Aplasia |
3.0% |
| Pseudomonas Infection |
2.8% |
| Bacteraemia |
2.7% |
| Insomnia |
2.7% |
| Pain |
2.7% |
| Epilepsy |
2.6% |
| Prophylaxis |
2.3% |
| Drug Therapy |
2.2% |
| Febrile Neutropenia |
2.2% |
| Intervertebral Discitis |
2.1% |
|
| Renal Tubular Disorder |
7.6% |
| Epilepsy |
7.0% |
| Pyrexia |
7.0% |
| Liver Disorder |
6.3% |
| Shock |
6.3% |
| Convulsion |
5.1% |
| Overdose |
5.1% |
| Renal Failure |
5.1% |
| Respiratory Failure |
5.1% |
| Rhabdomyolysis |
5.1% |
| Sepsis |
5.1% |
| Urinary Tract Infection |
5.1% |
| Confusional State |
3.8% |
| Hepatic Function Abnormal |
3.8% |
| Infection |
3.8% |
| International Normalised Ratio Increased |
3.8% |
| Multi-organ Failure |
3.8% |
| Pulmonary Congestion |
3.8% |
| Rash Maculo-papular |
3.8% |
| Rash Pustular |
3.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.6% |
| Drug Use For Unknown Indication |
20.2% |
| Hypertension |
5.4% |
| Pain |
4.4% |
| Multiple Myeloma |
4.0% |
| Bacterial Infection |
3.4% |
| Pulmonary Oedema |
3.0% |
| Pneumonia |
2.7% |
| Febrile Neutropenia |
2.6% |
| Prophylaxis |
2.5% |
| Prostate Cancer |
2.5% |
| Proteus Infection |
2.5% |
| Pseudomonas Infection |
2.5% |
| Rash |
2.5% |
| Thrombosis Prophylaxis |
2.5% |
| Prophylaxis Against Transplant Rejection |
2.4% |
| Anaemia |
2.0% |
| Shock |
1.9% |
| Crohn's Disease |
1.8% |
| Premedication |
1.7% |
|
| Vomiting |
12.7% |
| Systemic Inflammatory Response Syndrome |
9.6% |
| Sepsis |
8.1% |
| Septic Shock |
7.1% |
| White Blood Cell Count Decreased |
6.6% |
| Urosepsis |
5.6% |
| Gastrointestinal Perforation |
5.1% |
| Peritonitis |
4.6% |
| Renal Failure |
4.6% |
| Respiratory Failure |
4.1% |
| Transplant Failure |
4.1% |
| Pyrexia |
3.6% |
| Respiratory Arrest |
3.6% |
| Tachycardia |
3.6% |
| Pneumonia |
3.0% |
| Pulmonary Oedema |
3.0% |
| Renal Failure Acute |
3.0% |
| Thrombocytopenia |
3.0% |
| Febrile Neutropenia |
2.5% |
| Pancreatitis Acute |
2.5% |
|
| Interacting |
| Hypertension |
34.8% |
| Chronic Obstructive Pulmonary Disease |
13.0% |
| Pneumonia |
8.7% |
| Product Used For Unknown Indication |
8.7% |
| Coronary Artery Disease |
4.3% |
| Diabetes Mellitus |
4.3% |
| Flatulence |
4.3% |
| Hyperlipidaemia |
4.3% |
| Mycobacterial Infection |
4.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
4.3% |
| Type 1 Diabetes Mellitus |
4.3% |
| Urinary Tract Infection |
4.3% |
|
| Drug Interaction |
33.3% |
| Nausea |
33.3% |
| Tremor |
33.3% |
|
